What’s Driving Growth in the Axial Spondyloarthritis (axSpA) Market? Insights into Key Trends and Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What fueled the previous growth in the axial spondyloarthritis (axspa) market?
Over the past few years, the axial spondyloarthritis (axspa) market has experienced robust growth. A projected rise from $6.08 billion in 2024 to $6.58 billion in 2025, representing a compound annual growth rate (CAGR) of 8.3%, is anticipated. Factors contributing to the remarkable growth during the historic period include enhanced diagnostic criteria, the progression in biological treatment, heightened disease awareness, breakthroughs in genetic research, and advancements in clinical trials.
What will be the axial spondyloarthritis (axspa) market size in the future?
Anticipated to witness considerable expansion in the coming years, the market size for axial spondyloarthritis (axspa) is projected to reach $9.05 billion by 2029, yielding a compound annual growth rate (CAGR) of 8.3%. The escalating progression in the predicted span can be credited to developments in identifying biomarkers, customized treatments, digital health amalgamation, broadened therapy alternatives, and supportive health policies. The forecast period is characterized by notable trends like prompt intervention approaches, patient-focused care, technology-enabled healthcare through telemedicine and remote consultations, disease mechanism studies, and collective decision-making processes.
Get your axial spondyloarthritis (axspa) market report here!
https://www.thebusinessresearchcompany.com/report/axial-spondyloarthritis-axspa-global-market-report
What main drivers are fueling expansion in the axial spondyloarthritis (axspa) market?
The axial spondyloarthritis (axSpa) market is expected to expand due to the rising occurrence of spondyloarthritis. It’s a chronic disease that typically targets the axial skeleton, comprising the spine and sacroiliac joints. The growth in axial spondyloarthritis (axSpA) cases is related to an ageing population and injuries to the spine due to minor mishaps or other accidents. Multiple treatments are available for managing pain, controlling inflammation, and improving the life quality of patients suffering from axSpA. For example, Versus Arthritis’s Musculoskeletal Health Report 2023 disclosed in June 2023 that around 60,000 individuals were suffering from axial spondyloarthritis by 2022 in the UK. This UK-based charity for arthritis support also indicated that each year, close to 2,200 adults newly learn about their diagnosis of this ailment. Hence, the escalating incidence of axial spondyloarthritis (axSpa) propels the growth of the axial spondyloarthritis (axSpa) market.
What key areas define the segmentation of the global axial spondyloarthritis (axspa) market?
The axial spondyloarthritis (axSpA) market covered in this report is segmented –
1) By Types: Ankylosing Spondylitis (AS), Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
2) By Commercialized Therapies: Anti-Tumor Necrosis Factor Therapy (TNF), Anti-Interleukin Therapy (IL), Anti-Janus Kinase Therapy (JAK)
3) By Dosage Form: Tablets, Injections
4) By Treatment: Tumor Necrosis Factor (TNF) Alpha Inhibitors, Non-Steroidal Anti-Inflammatory Drugs (NSAID), Conventional Disease Modifying Anti-Rheumatic Drugs, Glucocorticoids, Interleukin Blockers
5) By End-Use: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacy Stores
Subsegments:
1) By Ankylosing Spondylitis (AS): Early-stage AS, Advanced-stage AS
2) By Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Symptomatic nr-axSpA, Asymptomatic nr-axSpA
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12590&type=smp
Who are the dominant players expanding their reach in the axial spondyloarthritis (axspa) market?
Major companies operating in the axial spondyloarthritis (axSpA) market include Johnson and Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca plc., Abbott Laboratories, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH., Horizon Therapeutics Public Ltd Co, Mitsubishi Tanabe Pharma Corporation, Ipsen Technologies Pvt Ltd., Kyowa Kirin Co. Ltd., Sun Pharmaceutical Industries Ltd., Acelyrin Inc., Nordic Bioscience A/S, Iroko Pharmaceuticals LLC
How are evolving market trends shaping axial spondyloarthritis (axspa) Strategies?
Innovations in product development are a major trend emerging in the axial spondyloarthritis (axSpA) market. To maintain their market position, major companies in the axial spondyloarthritis (axSpA) industry are focusing on the development of innovative drugs. An example of this is when UCB SA, a pharmaceutical company based in Belgium, gained approval from the New European Commission in June 2023 to market BIMZELX (bimekizumab). This drug is designed to help adults battling active axial spondyloarthritis (axSpA), non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) present with signs of inflammation as shown by raised C-reactive protein. These authorizations from the European Union (EU) denote the drug’s premier global marketing licenses for axial spondyloarthritis.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12590
Which regions are emerging as leaders in the axial spondyloarthritis (axspa) market?
North America was the largest region in the axial spondyloarthritis(axSpA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the axial spondyloarthritis (axSpA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Arthritis Monoclonal Antibodies Global Market Report 2024
Cervical Spondylosis Treatment Global Market Report 2024
TNF Alpha Inhibitors Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/tnf-alpha-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
